debrisoquin has been researched along with clomipramine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brøsen, K; Gram, LF; Nielsen, KK | 1 |
| Balant, LP; Balant-Gorgia, AE; Garrone, G | 1 |
| Aeschlimann, JM; Balant, LP; Balant-Gorgia, AE; Dayer, P; Garrone, G; Genet, C | 1 |
| Balant, L; Balant-Gorgia, AE; Zysset, T | 1 |
| Bertilsson, L | 1 |
1 review(s) available for debrisoquin and clomipramine
| Article | Year |
|---|---|
Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects.
Topics: Antidepressive Agents; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Clomipramine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; Drug Interactions; Ethnicity; Humans; Mediterranean Region; Metabolic Networks and Pathways; Mixed Function Oxygenases; Mutation; Nortriptyline; Polymorphism, Genetic; Sweden; White People | 2007 |
1 trial(s) available for debrisoquin and clomipramine
| Article | Year |
|---|---|
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
Topics: Adult; Aged; Clomipramine; Cytochrome P-450 Enzyme System; Debrisoquin; Depression; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Sparteine | 1992 |
6 other study(ies) available for debrisoquin and clomipramine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data.
Topics: Aged; Clomipramine; Debrisoquin; Depressive Disorder; Female; Humans; Hydroxylation; Imipramine; Middle Aged; Monitoring, Physiologic; Phenotype; Psychiatric Status Rating Scales | 1989 |
Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Benzodiazepines; Clomipramine; Debrisoquin; Depression; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxylation; Kinetics; Male; Methotrimeprazine; Middle Aged; Phenotype; Polymorphism, Genetic | 1986 |
High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer.
Topics: Allopurinol; Clomipramine; Debrisoquin; Depressive Disorder; Female; Humans; Hydroxylation; Kinetics; Middle Aged | 1987 |